stockportfolio.pro
Stocks / BMRN vs ICLR
BMRN vs ICLR
BioMarin Pharmaceutical Inc. and ICON Public Limited Company side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| BioMarin Pharmaceutical Inc. (BMRN) | ICON Public Limited Company (ICLR) | |
|---|---|---|
| Market cap | $10.9B | $11.1B |
| Revenue (latest FY) | $3.22B | $8.25B |
| Net income (latest FY) | $348.90M | $229.34M |
| Revenue growth (5y CAGR) | 11.6% | 2.1% |
| Net margin | 10.8% | 2.8% |
| Return on equity | 5.7% | 2.5% |
| P/E ratio | 40.4 | 50.0 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 5 | 4 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open BMRN — free Open ICLR — freeFrequently asked questions
Which is bigger, BMRN or ICLR?
ICON Public Limited Company is larger by market capitalization — $11.1B versus $10.9B.
Which grows faster, BMRN or ICLR?
Over the last five fiscal years, BioMarin Pharmaceutical Inc. grew revenue faster — 11.6%/yr versus 2.1%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.